Key Documents
MAB4381C3
Anti-TRA-1-81 Antibody, clone TRA-1-81, Cy3 conjugate
clone TRA-1-81, from mouse, CY3 conjugate
Synonym(s):
Podocalyxin, GCTM-2 antigen, Gp200, Podocalyxin-like protein 1
Sign Into View Organizational & Contract Pricing
Select a Size
All Photos(2)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
biological source
mouse
Quality Level
conjugate
CY3 conjugate
antibody form
saturated ammonium sulfate (SAS) precipitated
antibody product type
primary antibodies
clone
TRA-1-81, monoclonal
species reactivity
human
technique(s)
immunocytochemistry: suitable
isotype
IgM
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... PODXL(5420)
General description
420/250 kDa calculated
TRA-1-81 is expressed upon the surface of human teratocarcinoma stem cells (EC), human embryonic germ cells (EG) and human embryonic stem cells (ES). Both TRA-1-81 and TRA-1-60 recognize antigens that are associated with a pericellular matrix proteoglycan. TRA-1-60 reacts with a sialidase-sensitive epitope while TRA-1-81 reacts with an unknown epitope of the same molecule. TRA-1-81 is commonly used as marker of undifferentiated pluripotent human stem cells and is downregulated upon differentiation. TRA-1-81 has recently been identified as podocalyxin.
Immunogen
Human embryonal carcinoma cell line 2102Ep
Application
Evaluated by Immunocytochemistry in mouse embryonic stem cells (SCR012). Immunocytochemsitry Analysis: A 1:100 dilution of this antibody did not detect TRA-1-81 in mouse embryonic stem cells (SCR012).
Research Category
Stem Cell Research
Stem Cell Research
Research Sub Category
Pluripotent & Early Differentiation
Pluripotent & Early Differentiation
This Anti-TRA-1-81 Antibody, clone TRA-1-81, Cy3 conjugate is validated for use in ICC for the detection of TRA-1-81.
Biochem/physiol Actions
This antibody recognizes human TRA-1-81.
Physical form
Purified mouse monoclonal IgM conjugated to Cy3 in PBS with 0.1% sodium azide and 15mg/ml BSA.
Preparation Note
Maintain refrigerated at 2-8ºC protected from light in undiluted aliquots for up to 6 months from date of receipt.
Analysis Note
Control
H9 human embryonic stem cells
H9 human embryonic stem cells
Evaluated by Immunocytochemistry in H9 human embryonic stem cells.
Immunocytochemsitry Analysis: A 1:100 dilution of this antibody detected TRA-1-81 in H9 human embryonic stem cells.
Immunocytochemsitry Analysis: A 1:100 dilution of this antibody detected TRA-1-81 in H9 human embryonic stem cells.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Xinyu Liu et al.
Cell division, 15(1), 12-12 (2020-12-10)
Reprogramming somatic cells to induced pluripotent stem cells (iPSCs) has opened new therapeutic possibilities. However, karyotypic abnormalities detected in iPSCs compromised their utility, especially chromosomal aberrations found at early passages raised serious safety concerns. The mechanism underlying the chromosomal abnormality
Daniel Rodrigo Marinowic et al.
Molecular medicine reports, 15(4), 2049-2056 (2017-03-06)
Focal cortical dysplasia (FCD) is caused by numerous alterations, which can be divided into abnormalities of the cortical architecture and cytological variations; however, the exact etiology of FCD remains unknown. The generation of induced pluripotent stem cells (iPSCs) from the
Christian A Di Buduo et al.
eLife, 10 (2021-06-02)
Thrombocytopenic disorders have been treated with the Thrombopoietin-receptor agonist Eltrombopag. Patients with the same apparent form of thrombocytopenia may respond differently to the treatment. We describe a miniaturized bone marrow tissue model that provides a screening bioreactor for personalized, pre-treatment
Global Trade Item Number
| SKU | GTIN |
|---|---|
| MAB4381C3 | 04053252694707 |
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service